Favourable survival data from PAH registry

Local data from the Pulmonary Hypertension Society of Australian and New Zealand (PHSANZ) Registry confirms that Australian patients with PAH aren’t doing too badly considering limited access to combination therapy. In a study of 220 cases of predominantly idiopathic PAH diagnosed between the beginning of 2012 and the end of 2016, one-year survival was 95.6%, two-year ...

Already a member?

Login to keep reading.

© 2021 the limbic